ABCAM PLC/ADR (ABCZY) Raised to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of ABCAM PLC/ADR (OTCMKTS:ABCZY) from a sell rating to a hold rating in a research report report published on Wednesday morning, reports.

According to Zacks, “Abcam PLC distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam PLC is headquartered in Cambridge, the United Kingdom. “

Separately, ValuEngine raised ABCAM PLC/ADR from a hold rating to a buy rating in a research report on Thursday, May 23rd.

Shares of ABCZY opened at $18.64 on Wednesday. ABCAM PLC/ADR has a twelve month low of $12.52 and a twelve month high of $20.29.


Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.

Featured Story: Growth and Income Funds

Get a free copy of the Zacks research report on ABCAM PLC/ADR (ABCZY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ABCAM PLC/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABCAM PLC/ADR and related companies with's FREE daily email newsletter.